Literature DB >> 26487329

Biological Substrate of the Rapid Volumetric Changes Observed in the Human Liver During the Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy Approach.

Martin de Santibañes1, Agustin Dietrich2, Fernando A Alvarez2, Victoria Ardiles2, Monica Loresi3, Maximiliano D'adamo3, Eduardo de Santibañes2.   

Abstract

BACKGROUND: The associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) strategy induces rapid future liver remnant (FLR) hypertrophy. Hepatocyte cellular and molecular changes associated with liver hypertrophy during ALPPS remain ill-defined in humans.
METHODS: Patients undergoing the ALPPS approach between June 2011 and October 2014 were extracted. Biopsies from the FLR were obtained during the first and second stages. Hematoxylin-eosin staining and immunohistochemical analysis for expression of the proliferating cell nuclear antigen (PCNA) and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) were performed. The proliferative index was defined as: PCNA-TUNEL ratio.
RESULTS: Eleven of 34 patients treated were studied during both stages. Median FLR hypertrophy was 104 % in 6 days, with a mean difference between preoperative and postoperative volume of 361 ml (P < 0.001). The mean hepatocyte number increased from 52.7 cells/mm(2) in the first stage to 89.6 cells/mm(2) in the second stage (P = 0.001). PCNA expression increased by 190 % between stages with a linear correlation (r = 0.58) with macroscopic hypertrophy. The proliferative index increased from -3.78 cells/mm(2) in first stage to 2.32 cells/mm(2) in the second stage (P = 0.034).
CONCLUSIONS: The results of the present study indicate that the rapid FLR volumetric increase observed in ALPPS is accompanied by histological and molecular features of hepatocyte cell proliferation.

Entities:  

Keywords:  Future liver remnant; Hypertrophy; Immunohistochemical analysis; Liver failure; Two stage hepatectomy

Mesh:

Year:  2015        PMID: 26487329     DOI: 10.1007/s11605-015-2982-1

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  32 in total

Review 1.  Mechanisms of hepatic regeneration following portal vein embolization and partial hepatectomy: a review.

Authors:  Y Yokoyama; M Nagino; Y Nimura
Journal:  World J Surg       Date:  2007-02       Impact factor: 3.352

Review 2.  Strategies for safer liver surgery and partial liver transplantation.

Authors:  Pierre-Alain Clavien; Henrik Petrowsky; Michelle L DeOliveira; Rolf Graf
Journal:  N Engl J Med       Date:  2007-04-12       Impact factor: 91.245

3.  Posthepatectomy liver failure: a definition and grading by the International Study Group of Liver Surgery (ISGLS).

Authors:  Nuh N Rahbari; O James Garden; Robert Padbury; Mark Brooke-Smith; Michael Crawford; Rene Adam; Moritz Koch; Masatoshi Makuuchi; Ronald P Dematteo; Christopher Christophi; Simon Banting; Val Usatoff; Masato Nagino; Guy Maddern; Thomas J Hugh; Jean-Nicolas Vauthey; Paul Greig; Myrddin Rees; Yukihiro Yokoyama; Sheung Tat Fan; Yuji Nimura; Joan Figueras; Lorenzo Capussotti; Markus W Büchler; Jürgen Weitz
Journal:  Surgery       Date:  2011-01-14       Impact factor: 3.982

4.  Activated Nrf2 impairs liver regeneration in mice by activation of genes involved in cell-cycle control and apoptosis.

Authors:  Ulrike A Köhler; Svitlana Kurinna; Dominik Schwitter; Andrea Marti; Matthias Schäfer; Claus Hellerbrand; Tobias Speicher; Sabine Werner
Journal:  Hepatology       Date:  2014-06-18       Impact factor: 17.425

5.  Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings.

Authors:  Andreas A Schnitzbauer; Sven A Lang; Holger Goessmann; Silvio Nadalin; Janine Baumgart; Stefan A Farkas; Stefan Fichtner-Feigl; Thomas Lorf; Armin Goralcyk; Rüdiger Hörbelt; Alexander Kroemer; Martin Loss; Petra Rümmele; Marcus N Scherer; Winfried Padberg; Alfred Königsrainer; Hauke Lang; Aiman Obed; Hans J Schlitt
Journal:  Ann Surg       Date:  2012-03       Impact factor: 12.969

Review 6.  Oncologic resection for malignant tumors of the liver.

Authors:  Shefali Agrawal; Jacques Belghiti
Journal:  Ann Surg       Date:  2011-04       Impact factor: 12.969

7.  Outcomes after major hepatectomy in elderly patients.

Authors:  Krishna V Menon; Ahmed Al-Mukhtar; Amer Aldouri; Rajendra K Prasad; Peter A Lodge; Giles J Toogood
Journal:  J Am Coll Surg       Date:  2006-09-26       Impact factor: 6.113

8.  Functional hepatocellular regeneration in elderly patients undergoing hepatectomy.

Authors:  Alexandra I Fernandes; José G Tralhão; Ana Abrantes; Emir Hoti; Henrique Alexandrino; Bárbara Oliveiros; Margarida Ferreira; Maria F Botelho; Francisco C Sousa
Journal:  Liver Int       Date:  2014-01-09       Impact factor: 5.828

9.  Major hepatectomy for colorectal metastases: is preoperative portal occlusion an oncological risk factor?

Authors:  L Mueller; C Hillert; L Möller; G Krupski-Berdien; X Rogiers; D C Broering
Journal:  Ann Surg Oncol       Date:  2008-05-06       Impact factor: 5.344

10.  Three hundred and one consecutive extended right hepatectomies: evaluation of outcome based on systematic liver volumetry.

Authors:  Yoji Kishi; Eddie K Abdalla; Yun Shin Chun; Daria Zorzi; David C Madoff; Michael J Wallace; Steven A Curley; Jean-Nicolas Vauthey
Journal:  Ann Surg       Date:  2009-10       Impact factor: 12.969

View more
  2 in total

Review 1.  A literature review of associating liver partition and portal vein ligation for staged hepatectomy (ALPPS): so far, so good.

Authors:  Martin de Santibañes; Luis Boccalatte; Eduardo de Santibañes
Journal:  Updates Surg       Date:  2016-10-20

Review 2.  The role of associating liver partition and portal vein ligation for staged hepatectomy in the management of patients with colorectal liver metastasis.

Authors:  Juan Glinka; Victoria Ardiles; Juan Pekolj; Eduardo de Santibañes; Martin de Santibañes
Journal:  Hepatobiliary Surg Nutr       Date:  2020-12       Impact factor: 7.293

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.